Skip to main content
ScholarsBetaWeill Cornell Medicine

Publications

38 publications

Funding

4 grants

Active

3 grants
  • Co-I
    Evaluating the Impact of a Novel Educational Intervention to Improve Timely Colposcopy Follow-Up and Treatment Among High-Risk Populations
    National Cancer Institute · 2026–2031
    R01CA300794-01A1
  • Sub-PI
    EndoMAP: A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy with Atezolizumab forPatients with Recurrent or Persistent Endometrial Cancer
    Bristol-Myers Squibb · 2024–2027 · via Medical College of Virginia Foundation
    No publications yet
    VCUHS 242656-02
  • Sub-PI
    CTA - LAST MILE INITIAITVE - Self-sampling for HPV testing to Improve Cervical Cancer Prevention Trial (SHIP Study)
    National Cancer Institute · 2025–2026 · via Leidos Biomedical Research
    75N91019D00024
Completed grants (1)
  • PI
    Barriers to telemedicine utilization in Gynecologic Oncology outpatient clinic among Black and Latino women
    Foundation for Women's Cancer · 2021–2022
    FWC 212483-01

Clinical research

10 studies

Active

3 studies
  • PI
    Stereotactic Ablative Body Radiotherapy for oligometastatic gynecological malignancies: An institution-based review
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
  • PI
    NCI Cervical Cancer 'Last Mile' Initiative 'Self-Collection for HPV Testing to Improve Cervical Cancer Prevention' (SHIP) Trial LMI-001-A-S03
    NA · National Cancer Institute · OPEN TO ACCRUAL (as of 2025)
    Cervical Carcinoma; Human Papillomavirus Infection
    NCT06611540
  • PI
    A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
    NA · NRG Oncology · OPEN TO ACCRUAL (as of 2021)
    Ovarian Carcinoma
    NCT04251052
Completed & closed trials (7)
  • PI
    A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
    PHASE3 · GOG Foundation, Inc. · CLOSED TO ACCRUAL (as of 2026)
    Platinum-resistant Ovarian Cancer
    NCT06619236
  • PI
    A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
    PHASE1; PHASE2 · Alliance Foundation Trials, LLC · CLOSED TO ACCRUAL (as of 2025)
    Endometrial Cancer
    NCT04486352
  • PI
    Investigation of 3D Smart MRI in Surgical Efficiency and Planning
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
  • PI
    A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
    PHASE3 · NRG Oncology · IRB STUDY CLOSURE (as of 2023)
    Low Grade Fallopian Tube Serous Adenocarcinoma; Ovarian Low Grade Serous Adenocarcinoma; Primary Peritoneal Low Grade Serous Adenocarcinoma; Stage II Fallopian Tube Cancer AJCC v8; Stage II Ovarian Cancer AJCC v8; Stage II Primary Peritoneal Cancer AJCC v8; Stage III Fallopian Tube Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Primary Peritoneal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8
    NCT04095364
  • PI
    Barriers to telemedicine utilization in outpatient gynecologic oncology
    Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2023)
  • PI
    A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
    PHASE3 · NRG Oncology · CLOSED TO ACCRUAL (as of 2022)
    Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Dedifferentiated Carcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
    NCT03914612
  • PI
    A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
    PHASE3 · NRG Oncology · CLOSED TO ACCRUAL (as of 2022)
    Endometrial Endometrioid Adenocarcinoma; Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8; Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
    NCT04214067